𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

✍ Scribed by Yoichi Nakanishi; Yuji Kawarada; Nobuyuki Hirose; Kiyoshi Ninomiya; Masayuki Miyazaki; Naoki Miyazaki; Yukio Kurita; Hideaki Kanegae; Osamu Ohgushi; Kenichi Ogata; Hiroshi Yamazaki; Satoru Inutsuka; Nobuyuki Hara; Fukuoka Lung Cancer Study Group

Publisher
Springer
Year
1998
Tongue
English
Weight
340 KB
Volume
41
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Alternated approach with local irradiati
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer
✍ Pasquale Cornella; Gianfranco Scoppa; Antonio Daponte; Gennaro Musefta; Caterina πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 752 KB

Background. Prognosis of unresectable non-small cell lung cancer (NSCLC) patients is disappointing: their median survival time does not exceed 8-12 months. Recently, some authors reported an increased response rate and sometimes a prolonged survival for patients with intrathoracic disease treated wi

Combination chemotherapy with cisplatin
Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer
✍ F. Figoli; A. Veronesi; M. G. Trovo; D. Errante; M. Della Valentina; V. Zagonel; πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 447 KB

A total of 52 consecutive, previously untreated patients with small-cell lung cancer (SCLC) were scheduled to receive six cycles of a combination of etoposide (75 mg/m2 per day) and cisplatin (20 mg/m2 per day), each cycle given over 5 consecutive days. In all, 28 patients had extensive disease (ED)